Theravance Biopharma, Inc. (TBPH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 20M 40M 60M Q1 '13: 22K Q2 '13: 5K Q3 '13: 24K Q4 '13: 175K Q1 '14: 945K Q2 '14: 3M Q3 '14: 6.3M Q4 '14: 1.4M Q1 '15: 20.4M Q2 '15: 7.1M Q3 '15: 10.7M Q4 '15: 3.9M Q1 '16: 18.4M Q2 '16: 5.5M Q3 '16: 19.1M Q4 '16: 5.7M Q1 '17: 3.1M Q2 '17: 3.5M Q3 '17: 4.3M Q4 '17: 4.5M Q1 '18: 8.3M Q2 '18: 23.5M Q3 '18: 12.8M Q4 '18: 15.7M Q1 '19: 5.3M Q2 '19: 26.1M Q3 '19: 12.4M Q4 '19: 29.5M Q1 '20: 19.9M Q2 '20: 15M Q3 '20: 18.3M Q4 '20: 18.7M Q1 '21: 14.3M Q2 '21: 12.9M Q3 '21: 13.2M Q4 '21: 14.9M Q1 '22: 13.2M Q2 '22: 11.1M Q3 '22: 12.5M Q4 '22: 14.6M Q1 '23: 10.4M Q2 '23: 13.7M Q3 '23: 15.7M Q4 '23: 17.6M Q1 '24: 14.5M Q2 '24: 14.3M Q3 '24: 16.9M Q4 '24: 18.8M Q1 '25: 15.4M Q2 '25: 26.2M Q3 '25: 20M Q4 '25: 45.9M Q1 '26: 17.7M Q2 '26: 20.7M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q1 '13: -32.2M Q2 '13: -39M Q3 '13: -41.1M Q4 '13: -44.1M Q1 '14: -60M Q2 '14: -56.7M Q3 '14: -50.1M Q4 '14: -65.8M Q1 '15: -37.7M Q2 '15: -45.3M Q3 '15: -43.1M Q4 '15: -55.8M Q1 '16: -41.6M Q2 '16: -47.5M Q3 '16: -33.5M Q4 '16: -57.8M Q1 '17: -58.8M Q2 '17: -65.1M Q3 '17: -57M Q4 '17: -79.2M Q1 '18: -65M Q2 '18: -48.7M Q3 '18: -62.5M Q4 '18: -62.6M Q1 '19: -73.7M Q2 '19: -42.5M Q3 '19: -65.2M Q4 '19: -70.6M Q1 '20: -72.5M Q2 '20: -72.2M Q3 '20: -76.6M Q4 '20: -76.5M Q1 '21: -83.9M Q2 '21: -64.1M Q3 '21: -53.6M Q4 '21: -56.2M Q1 '22: -37.2M Q2 '22: -23.1M Q3 '22: -14.2M Q4 '22: -17.4M Q1 '23: -24.9M Q2 '23: -16.1M Q3 '23: -8.8M Q4 '23: -6.2M Q1 '24: -11.2M Q2 '24: -15.7M Q3 '24: -10.8M Q4 '24: -9.2M Q1 '25: -14.4M Q2 '25: -2.7M Q3 '25: -6.5M Q4 '25: 20M Q1 '26: -9.5M Q2 '26: -8.3M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Net Income Quarterly

-350M 0 350M 700M 1.1B Q1 '13: -32.2M Q2 '13: -39M Q3 '13: -41.1M Q4 '13: -44.1M Q1 '14: -60M Q2 '14: -58.2M Q3 '14: -54.5M Q4 '14: -64.3M Q1 '15: -42.5M Q2 '15: -47.6M Q3 '15: -47.3M Q4 '15: -44.8M Q1 '16: -42.1M Q2 '16: -47.2M Q3 '16: -34M Q4 '16: -67.3M Q1 '17: -65.3M Q2 '17: -66.3M Q3 '17: -66.9M Q4 '17: -86.9M Q1 '18: -65.1M Q2 '18: -40.8M Q3 '18: -59.4M Q4 '18: -50.2M Q1 '19: -72.6M Q2 '19: -39.8M Q3 '19: -58.4M Q4 '19: -65.6M Q1 '20: -83.1M Q2 '20: -62.9M Q3 '20: -73.6M Q4 '20: -58.4M Q1 '21: -79.7M Q2 '21: -52.4M Q3 '21: -35.3M Q4 '21: -32M Q1 '22: -25.9M Q2 '22: -8.2M Q3 '22: 916.6M Q4 '22: -10.4M Q1 '23: -22.1M Q2 '23: -15.6M Q3 '23: -8.9M Q4 '23: -8.5M Q1 '24: -11.7M Q2 '24: -16.5M Q3 '24: -12.7M Q4 '24: -15.5M Q1 '25: -13.6M Q2 '25: 54.8M Q3 '25: 3.6M Q4 '25: 61M Q1 '26: -4.9M Q2 '26: -5.9M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-160M -80M 0 80M 160M 240M Q1 '13: -28.5M Q2 '13: -24.3M Q3 '13: -32.9M Q4 '13: -35.2M Q1 '14: -44.8M Q2 '14: -51.4M Q3 '14: -36.4M Q4 '14: -42.5M Q1 '15: -56.5M Q2 '15: -46.6M Q3 '15: -32M Q4 '15: -33.7M Q1 '16: -26.3M Q2 '16: -32.1M Q3 '16: -12.4M Q4 '16: -28.1M Q1 '17: -50M Q2 '17: -44.5M Q3 '17: -62.3M Q4 '17: -44.2M Q1 '18: 49.8M Q2 '18: -61.5M Q3 '18: -49M Q4 '18: -52.2M Q1 '19: -81.2M Q2 '19: -48M Q3 '19: -44.6M Q4 '19: -64.4M Q1 '20: -55.1M Q2 '20: -53.3M Q3 '20: -77M Q4 '20: -64.9M Q1 '21: -69.9M Q2 '21: -50.1M Q3 '21: -45.4M Q4 '21: -42.4M Q1 '22: -26.1M Q2 '22: -14.7M Q3 '22: -22.1M Q4 '22: -124.1M Q1 '23: -11.2M Q2 '23: -12.4M Q3 '23: -2.5M Q4 '23: -854K Q1 '24: -1M Q2 '24: -4.4M Q3 '24: -5.2M Q4 '24: -902K Q1 '25: 43M Q2 '25: 208.1M Q3 '25: -6.5M Q4 '25: -6.1M Q1 '26: 73.3M Q2 '26: -7M Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q1 '13: -29.2M Q2 '13: -25M Q3 '13: -33.2M Q4 '13: -36.3M Q1 '14: -46.4M Q2 '14: -51.7M Q3 '14: -36.8M Q4 '14: -43.3M Q1 '15: -57.2M Q2 '15: -47.3M Q3 '15: -32.7M Q4 '15: -34.4M Q1 '16: -27M Q2 '16: -32.8M Q3 '16: -12.8M Q4 '16: -28.5M Q1 '17: -50.6M Q2 '17: -45.3M Q3 '17: -63.1M Q4 '17: -44.5M Q1 '18: 47.1M Q2 '18: -62.6M Q3 '18: -50.9M Q4 '18: -53.7M Q1 '19: -82.4M Q2 '19: -48.6M Q3 '19: -44.7M Q4 '19: -65.7M Q1 '20: -56.1M Q2 '20: -55.7M Q3 '20: -79.1M Q4 '20: -66.2M Q1 '21: -71.6M Q2 '21: -50.3M Q3 '21: -46.5M Q4 '21: -42.9M Q1 '22: -26.3M Q2 '22: -14.8M Q3 '22: -22.2M Q4 '22: -124.3M Q1 '23: -12.2M Q2 '23: -13.3M Q3 '23: -2.5M Q4 '23: -1.5M Q1 '24: -1.1M Q2 '24: -4.5M Q3 '24: -5.2M Q4 '24: -1.1M Q3 '25: -6.5M Q4 '25: -6.1M Q1 '13 Q4 '14 Q3 '16 Q2 '18 Q1 '20 Q4 '21 Q3 '23 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '18: 53.8M Q3 '18: 54.2M Q1 '19: 54.9M Q2 '19: 55.5M Q3 '19: 55.9M Q1 '20: 59.5M Q2 '20: 62.9M Q3 '20: 63.3M Q1 '21: 64.5M Q2 '21: 65.7M Q3 '21: 73.6M Q1 '22: 75.2M Q2 '22: 76.3M Q3 '22: 75.5M Q1 '23: 62.9M Q2 '23: 56.7M Q3 '23: 52.4M Q1 '24: 48.3M Q2 '24: 48.7M Q3 '24: 49M Q1 '25: 49.7M Q2 '25: 50.7M Q3 '25: 51.9M Q1 '26: 51.3M Q2 '26: 51.7M Q2 '18 Q3 '19 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-8.00 -4.00 0.00 4.00 8.00 12.00 Q4 '13: -4.92 Q1 '14: -5.80 Q2 '14: -6.40 Q3 '14: -6.83 Q4 '14: -7.46 Q1 '15: -6.86 Q2 '15: -6.45 Q3 '15: -6.13 Q4 '15: -5.34 Q1 '16: -5.15 Q2 '16: -4.79 Q3 '16: -4.12 Q4 '16: -4.25 Q1 '17: -4.42 Q2 '17: -4.63 Q3 '17: -5.17 Q4 '17: -5.45 Q1 '18: -5.40 Q2 '18: -4.89 Q3 '18: -4.72 Q4 '18: -4.00 Q1 '19: -4.10 Q2 '19: -4.06 Q3 '19: -4.01 Q4 '19: -4.26 Q1 '20: -4.34 Q2 '20: -4.62 Q3 '20: -4.73 Q4 '20: -4.48 Q1 '21: -4.32 Q2 '21: -4.12 Q3 '21: -3.44 Q4 '21: -2.95 Q1 '22: -2.05 Q2 '22: -1.36 Q3 '22: 11.26 Q4 '22: 11.54 Q1 '23: 11.53 Q2 '23: 11.36 Q3 '23: -0.95 Q4 '23: -0.97 Q1 '24: -0.86 Q2 '24: -0.92 Q3 '24: -1.01 Q4 '24: -1.15 Q1 '25: -1.18 Q2 '25: 0.24 Q3 '25: 0.57 Q4 '25: 2.03 Q1 '26: 2.20 Q2 '26: 1.01 Q1 '14 Q4 '15 Q3 '17 Q2 '19 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.